Project Grant K99CA297044
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$171K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $942,442 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Dana-Farber Cancer Institute (DFCI) to identify the mechanisms driving the rapid evolution of cancer genomes. The key objectives are to understand the processes of chromothripsis, a catastrophic mutational event involving massive chromosome rearrangement, and chromoplexy, another poorly understood mutational process common in cancer. Using...
This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022. The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach....
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The National Cancer Institute (NCI) awarded a $667,792 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Chicago. The five-year grant, running from June 1, 2024 to May 31, 2029, will fund research to develop "ultra-potent, pharmacologically stable" synthetic transcriptional repressors (STRs) that can directly inhibit the oncogenic activity of the transcription factors XBP1 and HIF1A. These targets are critical for the survival and growth of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $527,159 to Brigham & Women's Hospital Inc. for a research project titled "DNA Damage-Related Stemness Program During BRCA1 Breast Cancer Initiation." The project aims to study how the accumulation of DNA damage, particularly interstrand crosslink damage, in BRCA1-deficient luminal mammary cells may induce a fetal mammary stem cell-like program leading to breast...
The U.S. National Cancer Institute awarded a $450,429 Project Grant (R21CA289134) under the Cancer Treatment Research program (CFDA 93.395) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The objective of this 2-year project is to advance understanding of how the MUC1-C protein contributes to immune evasion in EGFR-mutant non-small cell lung cancer (NSCLC), and to evaluate novel antibody-drug conjugate (ADC) therapies targeting MUC1-C alone and in combination with immune...
This federal Project Grant award for $456,048.00, granted by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at Cold Spring Harbor Laboratory on the mechanisms by which breast cancer disrupts normal circadian rhythms in glucocorticoid hormones. The key objectives are to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs in response to breast cancer, identify the underlying...
This $369,108 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) will support research by the Broad Institute, Inc. to investigate mechanisms of drug resistance in BRAF-mutant melanoma. The goal is to demonstrate that melanomas developing resistance to BRAF and MEK inhibitors can be sensitized to lethal MAPK pathway hyperactivation, potentially overcoming resistance and leading to tumor eradication. The research will employ...
The National Cancer Institute (NCI) awarded a $101,458 Project Grant through the Cancer Research Manpower (CFDA 93.398) program to the University of Washington for the project "QUANTITATIVE CHARACTERIZATION OF TUMOR HETEROGENEITY USING HABITAT IMAGING FOR THE PREDICTION OF PATIENT OUTCOME IN TRIPLE NEGATIVE BREAST CANCER". This 2-year grant supports research to employ quantitative magnetic resonance imaging (MRI) techniques to spatially map and characterize tumor microenvironmental...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...